In a regulatory filing, Cogent Biosciences (COGT) disclosed that its Chief Commercial Officer Cole Pinnow bought 43.8K shares of common stock on January 14th in a total transaction size of $332.4K.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COGT:
- Cogent Biosciences price target lowered to $14 from $17 at H.C. Wainwright
- Cogent Biosciences highlighted key 2025 milestones
- Cogent Biosciences downgraded to Hold from Buy at Needham
- Cogent Biosciences announces updates results from SUMMIT
- Cogent Biosciences announces updated data from ongoing Phase 2 APEX trial